PDCD1 and fetal growth restriction: In studies on cynomolgus monkeys, injecting high doses of the anti-PD-1 agent Nivolumab (>10 times the clinical dose) resulted in an increased risk of fetal growth restriction, preterm birth, and fetal and neonatal death compared to placebo [26].